ScripBristol Myers Squibb is three years away from facing generic and biosimilar competitors for its two top-selling products – Eliquis (apixaban) and Opdivo (nivolumab), which delivered 52% of the company
ScripStrong growth across multiple cancer indications as well as price rises saw Merck & Co’s PD-1 inhibitor Keytruda (pembrolizumab) increase its revenues by 18% in 2024, putting it more than $12bn ah
ScripBristol Myers Squibb obtained two US Food and Drug Administration approvals during the week of 7 April for combination therapy with its immuno-oncology stalwarts Opdivo (nivolumab) and Yervoy (ipilimu
ScripA Paradoxical Stock Move Of all the stock price reactions in the fourth-quarter 2024 earnings season, the last – that of Bayer – was the most perplexing. Bayer’s stock price opened up in Frankfurt by